Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14239248 | 0.91 | HRH3 (0.41) | HCAR3TRPV1HRH3ALDH1A1AOC3 | |
| SCHEMBL15247307 | 0.88 | TRPV1 (0.42) | HCAR3TRPV1TLR7HRH3HTR2A | |
| SCHEMBL11990178 | 0.85 | TRPV1 (0.39) | HCAR3TRPV1HTR2AHRH1RAB9A | |
| SCHEMBL11989550 | 0.82 | HCAR3 (0.38) | HCAR3TRPV1TLR7HRH3HTR2A | |
| SCHEMBL11990167 | 0.82 | HCAR3 (0.39) | HCAR3TRPV1TLR7RAB9AKMT2A | |
| SCHEMBL11990206 | 0.81 | GBA1 (0.41) | HCAR3HTR2AHRH1KMT2AALDH1A1 | |
| SCHEMBL14238178 | 0.81 | HCAR3 (0.38) | HCAR3TRPV1RAB9AKMT2AALDH1A1 | |
| SCHEMBL14239256 | 0.80 | KCNH2 (0.37) | HCAR3RAB9AKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL14349197 | 0.78 | HRH3 (0.44) | HCAR3TRPV1TLR7HRH3HRH1 | |
| SCHEMBL7245666 | 0.74 | HRH3 (0.44) | HCAR3TLR7HRH3ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309963-A1 | 5-CYANO-4- (PYRROLO [2,3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309963-A1 | 5-CYANO-4- (PYRROLO [2,3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K5, CDK5, MAP4K2 | HCAR3 2834/4885TRPV1 2860/4885TLR7 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.